Press Release

Home / Press Release (Page 2)

BERLIN, Germany, January 15th, 2020 – AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028) provides an update on its strategy to become one of the leading importers of European Union - Good Manufacturing Practices (EU-GMP) medical cannabis into Germany through its network of suppliers from Canada, Europe and other non-European countries.   2019 Highlights Share floatation on the Canadian Securities and Frankfurt Stock Exchanges, Secured C$750,000 (€500,000) revolving drawdown loan facility, Raised C$1.5-million (€1,035,000) in Series A...

BERLIN, Germany, January 8, 2020 – AMP German Cannabis Group Inc. (“AMP” or the “Company”) (CSE: XCX) (FSE: C4T, ISIN: CA00176G1028) announces a non-brokered placement of up to 8,000,000 common shares of the Company at a price of $0.25 per share for gross proceeds of up to $2,000,000. The Company intends to use the net proceeds from the offering to fund its import business, general corporate purposes and working capital. All securities issued pursuant to the offering will be subject to a...

Berlin and Erfurt, Germany - November 18, 2019 –– AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028) announces the Thuringian State Office for Consumer Protection (Thueringer Landesamt fuer Verbraucherschutz) (“TLV”) has granted an import licence for cannabis products for medical purposes for Germany according to Section 72 of the German Medicine Law (Arzneimittelgesetz - AMG) to Alternative Medical Products GmbH (“AMP Germany”), a wholly-owned subsidiary of AMP.   The TLV deals with fundamental matters of economic consumer protection and...

AMP to supply the growing Germany market with pharmaceutical medical cannabis imported from Canada ERFURT and BERLIN, Germany, October 15, 2019 – AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028) through its wholly-owned subsidiary AMP Alternative Medical Products GmbH (“AMP Germany”) has entered into a four-year, non-exclusive, distribution agreement with CC Pharma GmbH (“CC Pharma”), a leading distributer of EU-pharmaceuticals products to more than 13,000 pharmacies throughout Germany.  The agreement provides for monthly shipments of imported European Union...

BERLIN, Germany, October 10, 2019 –– AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028) announces that it has begun conducting an European Union (EU) Good Manufacturing Procedure (EU-GMP) audit of its supply chain logistics in Germany to ensure that the quality and integrity of pharmaceutical goods during transportation and storage is maintained throughout the supply chain from the supplier to the German patient.     EU-GMP certification is an internationally recognized system that ensures all pharmaceutical goods, including medical cannabis,...

BERLIN, Germany, October 8, 2019 –– AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028) announces that it has entered into a non-binding memorandum of understanding to purchase up to 1,200 kilograms of either branded or white-labeled European Union - Good Manufacturing Practice (EU-GMP) medical cannabis flower annually from an Alberta based supplier with a cultivation and processing licence from Health Canada (“Alberta LP”).        AMP and the Alberta LP will begin imports upon the Alberta LP receiving a sales...

BERLIN, Germany, September 17, 2019 –– AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028) announces that one of its prospective medical cannabis supplier, Pure Life Cannabis Corp. (“Pure Life”), has completed its European Union Good Manufacturing Practice (“EU-GMP”) gap analysis and will undergo an EU-GMP audit before calendar year-end.  Upon passing the EU-GMP audit, Pure Life will be subject to an EU-GMP inspection and certification by German State officials.       AMP and Pure Life announced on February 7, 2019...

BERLIN, Germany, September 6, 2019 – AMP German Cannabis Group Inc. (“AMP” or the “Company”) (CSE: XCX), (FSE: C4T, ISIN: CA00176G1028) announces that it has granted incentive stock options to purchase up to 2,120,000 common shares of the Company to certain directors, officers, employees and consultants in accordance with its stock option plan, including options to purchase up to 1,175,000 shares to certain directors and officers. Each option vests immediately has an exercise price of $0.50 per share and is exercisable...

BERLIN, Germany, September 4, 2019 – AMP German Cannabis Group Inc. ("AMP" or the "Company") (formerly "Chinook Tyee Industry Limited") (CSE: XCX), (FSE: C4T), (ISIN: CA00176G1028) announces the commencement of trading of its common shares on the Canadian Securities Exchange (CSE).  The Company's common shares were delisted from the TSX Venture Exchange at the close of market on September 3, 2019. The Company also announces that it has updated investment policy to enhance shareholder value from investments in the European medical...

BERLIN, Germany, August 22, 2019 – Chinook Tyee Industry Limited ("Chinook" or the "Company") (TSXV: XCX), (Frankfurt: C4T: ISIN: CA16961T2083) announces that the Canadian Securities Exchange ("CSE") has approved the listing of the Company's Class A Voting Common Shares Without Par Value ("Common Shares") and will begin trading at market open on September 4, 2019 under the Company's current symbol, "XCX" ("CSE Listing").  The Company also announces that it has changed its name to "AMP German Cannabis Group Inc." and its...